Figure S4 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression

Naveen Kumar Tangudu; Raquel Buj; Hui Wang; Jiefei Wang; Aidan R. Cole; Apoorva Uboveja; Richard Fang; Amandine Amalric; Baixue Yang; Adam Chatoff; Claudia V. Crispim; Peter Sajjakulnukit; Maureen A. Lyons; Kristine Cooper; Nadine Hempel; Costas A. Lyssiotis; Uma Chandran; Nathaniel W. Snyder; Katherine M. Aird

doi:10.1158/2767-9764.25738374

Abstract

shp16 tumor bearing mice treated with methotrexate have a trend towards a survival advantage; and methotrexate does not affect body weight or blood cell counts. Related to Figure 5.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tangudu et al. (2024) studied this question.

synapsesocial.com/papers/68e6bd48b6db64358763de7a https://doi.org/10.1158/2767-9764.25738374

View Full Paper

Ask AI

Bookmark

Share

Figure S4 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression

Abstract

Discussion

Cite This Study

Figure S4 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers